Biomet Q2 results in line, save for a few stragglers
This article was originally published in Clinica
Executive Summary
Despite reporting an 18% increase in revenues and a 10% boost in profit, orthopaedics company Biomet saw its share price take a knock - falling almost 7% to a low of $43.73 - on the day it announced its second quarter results (December 15).